Screening centers will focus on disease-related biology, including diabetes, cancer, and steroid hormone-related metabolic disorders.
Researchers from The John S. Dunn Gulf Coast Consortium for Chemical Genomics (GCC-CG) will use Invitrogen’s gene expression and imaging portfolio to discover biomedically relevant aspects of gene and protein expression. The screening centers will focus on aspects of disease-related biology, including diabetes, cancer, and steroid hormone-related metabolic disorders.
Scientists at facilities at Baylor College of Medicine and University of Texas Health Science Center, part of GCC-CG, will use their expertise in high-content, high-throughput image-based screening and quantitative gene expression, respectively, to maximize the biological content from these experiments. Initial experiments will use Invitrogen’s human kinase, human nuclear receptor and mouse nuclear receptor collections. The quantitative effects of the siRNA molecules on gene and protein expression will be assessed using Invitrogen’s SYBR GreenER™ real-time qPCR technology and image-based tools from its Molecular Probes™ portfolio.
Additional participating members of the GCC-CG are Rice University, University of Houston, The University of Texas M. D. Anderson Cancer Center, and The University of Texas Medical Branch at Galveston.
